Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma

Neoplasma

Volumn 59, Issue 2, 2012, Pages 137-141

  Wang, Z ^a,b   Zheng, T ^c   Wu, Q ^b   Wang, J ^a   Wu, C ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Intrahepatic cholangiocarcinoma; MTOR pathway; Phosphorylation; Prognosis; Targeted therapy

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PEROXIDASE; S6 KINASE; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADULT; AGED; ANTIGEN RETRIEVAL; ARTICLE; BILE DUCT CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CANCER GRADING; ENZYME IMMUNOASSAY; FOLLOW UP; LIVER TUMOR; METABOLISM; MORTALITY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CHOLANGIOCARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863833291     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_018     Document Type: Article

References (17)

1. FARGES O, FUKS D. Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol Clin Biol 2010; 34: 191-199. http://dx.doi. org/10.1016/j.gcb.2010.01.006
2. SIRICA AE, DUMUR CI, CAMPBELL DJ, ALMENARA JA, OGUNWOBI OO, et al. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol 2009; 7: S68-78. http://dx.doi. org/10.1016/j.cgh.2009.08.023
3. ZONCU R, EFEYAN A, SABATINI DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35. http://dx.doi.org/10.1038/nrm3025
4. YECIES JL, MANNING BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl) 2011; 89: 221-228.
5. WANDER SA, HENNESSY BT, SLINGERLAND JM. Nextgeneration mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231-1241. http://dx.doi.org/10.1172/JCI44145
6. ROYCHOWDHURY A, SHARMA R, KUMAR S. Recent advances in the discovery of small molecule mTOR inhibitors. Future Med Chem 2010; 2: 1577-1589. http://dx.doi. org/10.4155/fmc.10.233
7. SHINTO O, YASHIRO M, TOYOKAWA T, NISHII T, KAIZAKI R, et al. Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer 2010; 10: 652. http://dx.doi. org/10.1186/1471-2407-10-652
8. NAVÉ BT, OUWENS M, WITHERS DJ, ALESSI DR, SHEPHERD PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999; 344 Pt 2: 427-431.
9. BROWN RE, ZHANG PL, LUN M, ZHU S, PELLITTERI PK, et al. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 2006; 36: 273-282.
10. BROWN RE, ZOTALIS G, ZHANG PL, ZHAO B. Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol 2008; 1: 333-342.
11. VILLANUEVA A, CHIANG DY, NEWELL P, PEIX J, THUNG S, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983. http://dx.doi. org/10.1053/j.gastro.2008.08.008
12. CHUNG JY, HONG SM, CHOI BY, CHO H, YU E, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 2009; 15: 660-667. http://dx.doi.org/10.1158/1078-0432.CCR-08-1084
13. HERBERGER B, PUHALLA H, LEHNERT M, WRBA F, NOVAK S, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007; 13: 4795-4799. http://dx.doi.org/10.1158/1078-0432.CCR-07-0738
14. NOSKE A, LINDENBERG JL, DARB-ESFAHANI S, WEICHERT W, BUCKENDAHL AC, et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 2008; 20: 1409-1417.
15. NO JH, JEON YT, PARK IA, KIM YB, KIM JW, et al. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 2011; 121: 8-12. http://dx.doi.org/10.1016/j.ygyno.2010.12.364
16. HAY N, SONENBERG N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945. http://dx.doi. org/10.1101/gad.1212704
17. GINGRAS AC, RAUGHT B, GYGI SP, NIEDZWIECKA A, MIRON M, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15: 2852-2864.